Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.

Abstract

6008Background: Anti-PD-1/PD-L1 are active in metastatic oropharynx squamous cell carcinoma (OPC). Durvalumab (durva) and tremelimumab (tremi) target respectively PD-L1 and CTLA-4, which in combina...